Abstract
We thank Dr. Tchetina for their interest in our article,1 and we appreciate the opportunity to respond to their Letter to the Editor.2 In the letter and their recent publication, Tchetina et al describe the utility of gene expression analyses using peripheral blood mononuclear cells (PBMCs) from patients with rheumatoid arthritis (RA) to predict clinical response to tofacitinib (TOF).2,3
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
